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Abstract: The oncological safety of treating multiple ipsilateral breast cancers (MIBCs) with types of 
breast conserving surgery (BCS) compared to mastectomy remains uncertain. This is predicated on the 
absence of any randomised controlled trials or high-quality protocol defined prospective cohort studies. A 
single recently published systematic review by the first author, reports its summarised results in this review. 
Fundamentally the important question is the evaluation of clinical safety following BCS compared to 
mastectomy for treating MIBC, which is reported in only six studies. Consequently, current evidence doesn’t 
support the latest St Gallen consensus suggesting the possibility of using BCS to treat all MIBC. There is 
minimal comparative outcomes data on multicentric (MC) cancers compared to multifocal (MF) cancers 
comparing BCS or mastectomy. There is also poor evidence of clinical outcomes following therapeutic 
mammoplasty (TM) for MIBC compared to mastectomy. The potential recommendation of two potential 
radiotherapy boosts to separate lumpectomy sites following BCS for MC cancers remains a novel treatment 
concept whose feasibility will be evaluated in the forthcoming NIHR funded randomised feasibility trial 
called MIAMI. This is a world first attempt to assess the feasibility of a randomised trial design alongside 
the on-going Alliance registry study (ACOSOG, American College of Surgeons Oncology Group Z11102) 
in the USA, in which there is no comparative evaluation of mastectomy outcomes. The MIAMI trial aims 
to assess the clinical safety of multiple lumpectomies combined with TM compared to the standard of 
mastectomy in MIBC stratified by MF or MC cancers. There is limited evidence on the impacts of inter-
tumoral heterogeneity relating to breast cancer subtypes in relation to individualised treatments and 
recommendations for types of breast surgery. Recent studies have highlighted the potential contributions 
of stromal epigenetic changes that are currently poorly understood regarding their contributions to either 
clinical unifocal or MF cancers.
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Introduction
The true incidence of multiple ipsilateral breast cancers 
(MIBCs) is currently unknown, however this is predicted 
to range from 20–25% following a recent systematic 
review of the English literature from May 1988 to July 
2015 (1). The prevalence of MIBC varies from or 5–60% 
in published series (2-5). The term MIBC denotes either 
multifocal (MF) breast cancers that occur within close 
proximity separated by approximate radiological distances 
of 20–50 mm of normal tissue, or multicentric (MC) 
cancers occurring further apart in the breast at distances 
exceeding 50 mm (6). Historically these definitions have 
varied across studies resulting in clinical confusion, and 
confounding standardised study comparisons. The use of 
the term breast “quadrants” describing MF cancers within 
one “quadrant”, or MC cancers in separate “quadrants”, 
should now also be reconsidered, precluding inter-study 
reproducibility or diagnostic accuracy when informing the 
current management of MIBC (1). MF cancers comprise 
a far larger proportion of MIBC as reported in the 
EORTC AMAROS trial where they comprised 33% of 
cases (342/1,026) (7). Today, new radiological techniques 
such as magnetic resonance imaging (MRI) and enhanced 
mammography are increasing the diagnosis of MIBC, and 
underlining the importance of increasing our understanding 
of current evidence guiding treatment recommendations (8). 
Increasingly, emerging knowledge of breast cancer subtypes 
and associated heterogeneity in parallel with the launch 
of the UK Genomics 100k project and specialist research 
suggests that future definitions of MIBC may depend 
on the genomic homogeneity or heterogeneity between 
breast cancers, characterising either MF or MC MIBC, 
respectively (9). Therefore, future classifications of MIBC 
are likely to be genomic in nature, and comprise not only 
analyses of each cancer focus, but also of their surrounding 
stromal tissue (10). These exciting research areas will be 
further described under our biological understanding of 
MIBC. It is hoped that current and future high-quality 
studies and randomised trials in the UK, Europe and the 
USA will address some of these important issues (8).
MIBC breast cancer, what we know so far in 
relation to unifocal cancers
Although we anticipate increasing diagnoses of MIBC, 
little is known about their biological characteristics. Many 
retrospective studies have consistently shown a correlation 
between multifocality/multicentricity (MIBC) and the 
rate and extent of lymph node metastases (1,5). This is 
reported in 42% to 59% of cases (4,5,11,12), however this 
observation was not substantiated by the meta-analysis 
of Vera-Badillo et al. (13). Such varied observations may 
hypothetically relate to inconsistencies in TNM (tumor-
node-metastasis) staging classifications, which fail to take 
account of global cancer volumes whose importance exceeds 
that of unifocal cancers. MIBC may more frequently be 
associated with poor prognostic factors compared with 
unifocal disease (14-18). These associations are potentially 
suggestive that MIBC are biologically more aggressive 
with a propensity for metastases. Whether MIBC is an 
independent adverse prognostic factor in breast cancer 
remains controversial. Considering the arbitrary distinction 
between multifocality and multicentricity, multiple 
simultaneous ipsilateral and synchronous lesions (MIBC) 
are now generally defined as multifocal breast cancers in the 
latest edition of the TNM classification, providing that they 
are macroscopically distinct and measurable using current 
traditional pathological and clinical tools (19). The latest 
version of the AJCC staging classification of tumour size (T) 
stipulates recording the largest diameter of the largest focus 
and not the summation of all foci, however, it recommends 
stipulating the code “m” is used to indicate multiple cancers 
or alternatively the total numbers of invasive cancers should 
be described, for example if the largest focus is 30 mm 
out of three invasive cancers then the T staging will be 
pathological (p) T2[3] (19). Furthermore, the biology of 
MIBC breast cancer is also now taken into consideration 
in the TNM classification, recommending evaluations of 
receptors [estrogen receptor (ER), progesterone receptor 
(PR) and human epidermal growth factor receptor 
(HER2)] on at least two foci or on all foci depending on 
morphological similarities or differences (19).
Coombs and Boyages (20) recommended using aggregate 
cancer dimensions, thereby upstaging most MIBC to 
more advanced stages, with rates of lymph node positivity 
stage-for-stage comparable to those of unifocal cancers. 
It is questionable whether the current TNM staging will 
amend its recommendations based on emerging high 
quality translational studies in future. Positive lymph node 
involvement was reported in 44–50% of MIBC cases, 
compared with 38% of unifocal cancers (7,14,15,17,20,21). 
Dual-localization sentinel lymph node biopsy (SLNB) is 
accurate diagnostically in MIBC (7). A subset of women 
with MIBC (342, 8.5%) in the European Organisation 
for Research and Treatment of Cancer 10981–22023 
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AMAROS (After Mapping of the Axilla: Radiotherapy or 
Surgery) trial had a 61% rate of SLNB positivity (105/171), 
compared with 28% of those with unifocal cancers (7,22). 
This suggests the safety of a sentinel lymph node biopsy in 
MIBC.
Some of the reviewed studies (16,23) reported worse 
disease-free survival (DFS) and overall survival for MIBC 
than for single cancers, yet other studies (24,25) noted 
similar outcomes. MC cancers (but not MF cancers) were 
distinguished by significantly worse overall (P=0.009) 
and DFS (P<0.001) compared with unifocal cancers (16). 
However, this was negated by a complete pathological 
response after neoadjuvant chemotherapy, and independent 
of type of surgery (16,26). Similarly, Wolters et al. (17) 
reported a significant association between MIBC and 
relapse-free survival in a study of 1,862 MIBC compared 
with 7,073 unifocal cancers (P=0.007); however, this 
finding related to clinical non-adherence to German 
guidelines. Weissenbacher and colleagues (27) confirmed 
a significant association between MIBC and overall breast 
cancer recurrence (P=0.001) in matched-pair multivariable 
analyses of MIBC compared with unifocal cancers (288 in 
each group). These conflicting reports support a future 
review of current TNM staging for MIBC. A meta-analysis 
by Vera-Badillo et al. (13) showed an apparent decreased 
overall survival in MIBC compared to unifocal cancers 
(HR =1.65, 95% CI: 1.07–2.52, P=0.02),  without 
differences in recurrence free survival, however, the data are 
controversial in large part due to inter-study heterogeneity. 
MIBC (n=110) were independently predictive of local recurrence 
at 5 and 10 years compared to matched unifocal controls (n=263) 
independent of the type of surgery, albeit limited by a small 
retrospective study (HR =3.009, P=0.025) (28). Suggestions 
that unifocal cancers are biologically different from MIBC, 
renders the comparisons of breast conserving surgery (BCS) 
in MIBC to unifocal cancers as illogical and therefore is 
not an ideal evaluation on which to inform evidence-based 
treatment recommendations.
Biological features of MIBC cancers
MIBCs may arise secondarily to: intra-mammary spread of 
a single carcinoma, simultaneous outgrowth of independent 
cancer foci, or multiple carcinomas arising simultaneously 
via extensive intraductal or pre-invasive ductal carcinoma 
in situ (DCIS) (3). The third proposition more likely 
underlies the biological aetiology of MF cancers, few 
studies consolidate these theories by evaluating either 
histological or immunohistochemical characteristics of 
individual foci within MIBC (19). The majority of MIBC 
appear to be clonally related, potentially indicative of 
intramammary metastases reflecting a more aggressive 
phenotype compared to unifocal cancers (3). Initial 
observations demonstrated reasonable concordance of ER, 
PR and HER2 between multiple cancers in the breast (3). 
This implies that characterization of only one lesion, in the 
context of similar histological grades or receptor subtypes, 
should adequately individualise treatments (19). However, 
potential inter-lesional heterogeneity suggests that the 
exclusive characterization of the largest cancer focus is 
insufficient (29). Additional evidence shows that MIBC 
are associated with a significantly higher Nottingham 
Prognostic Index (NPI) compared to unifocal cancers 
(3,30). Proportionally, grade 1 histological cancers are also 
lower in MC cancers compared to MF and unifocal cancers, 
respectively (5). MF cancers were invasive ductal cancers 
with extensive DICS, compared to MC cancers that were 
invasive lobular as reported by Kanumuri et al. (5). 
Molecular subtyping in breast cancers provides 
therapeutic and prognostic stratification (31,32). There is 
limited evidence on associations between MIBC and five 
molecular subtypes, compared with the subtype distribution 
in unifocal cancers (14). A comprehensive IHC subtyping 
algorithm (six biomarkers) that can distinguish luminal 
B from luminal A cancers, and basal from triple-negative 
disease, has potential clinical implications (32-34). Luminal 
cancers had a lower risk of 5-year LRR than HER2-
positive or triple-negative unifocal disease after BCS in 
12,500 patients (35). Ataseven and co-workers (16) reported 
increased associations between ER-positive and HER2-
positive genotypes in MIBC, compared with unifocal 
cancers (P<0.001). Similarly, Moon et al. (36) reported fewer 
triple-negative MIBC than unifocal cancers. Lynch and 
colleagues (24) showed no significant associations between 
MIBC (906 patients) and molecular subtypes. Given the 
growing appreciation of intertumoral heterogeneity in 
MIBC, molecular characterization of a single focus may 
underestimate the molecular landscape (19). Standard 
phenotyping and genotyping of each cancer in MIBC 
should underpin future treatment recommendations (8,19). 
Imaging for MIBC breast cancers
Clinically occult cancers may be treated adequately by 
adjuvant whole-breast RT after BCS (29). The incidence 
of clinically and radiologically detected MIBC ranges from 
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10% to 24% of all breast cancers (15-17,24), increasing with 
time from earlier to later studies. Two recent meta-analyses 
showed how MRI helped identify additional conventionally 
occult lesions in 15–27% of cases (37,38). This apparent 
doubling in incidence of MIBC over the 10 years between 
1990 and 2000 may be due in part to improved breast 
imaging (digital mammography, ultrasonography and 
MRI) and increased screening (38). Standard imaging of 
MIBC should comprise digital mammography, ultrasound 
examination and MRI, with biopsy confirmation of any 
additional suspected cancers on MRI to minimize their 
misdiagnosis, which occurs in 30% of “lesions” (38,39), as 
recommended by the EUSOMA working guidelines. 
Current evidence
The latest St Gallen consensus endorses the technical 
and cosmetic feasibility of treating some MIBC (MF and 
MC) with BCS, however, this endorsement is unsupported 
by high quality comparative clinical evidence to date, 
with no randomised trials or prospective cohort studies 
showing unequivocal oncological safety of BCS compared 
to mastectomy (40). Only six retrospective studies in a 
systematic review out of 24 eligible studies compared local 
regional recurrence (LRR) outcomes after BCS versus 
mastectomy (1,8). Remaining studies comprised seven 
case studies and thirteen studies evaluating the clinical 
outcomes of BCS for MIBC versus unifocal cancers (1,8). 
Two independent authors used the Newcastle Ottowa 
scoring system to assess study quality and showed these 
within the systematic review to be of poor to moderate 
quality (1). A meta-analysis was used to evaluate the rates 
of LRR after BCS compared to mastectomy in seven 
studies (1). A Forest plot of seven studies showed study 
homogeneity and apparently equivalent rates of LRR (risk 
ratio 0.94, 95% CI: 0.65–1.36) (1). This interpretation 
is contingent on extensive study limitations with the 
preferential selection of BCS for low risk cancers compared 
to mastectomy for aggressive cancers, consequently limiting 
the value of such a meta-analysis.
Observational studies evaluating treatments for MIBC 
have shown wide variation in clinical outcomes (1). There 
have also been wide ranging expert opinions on optimal 
surgical treatments (31,41). Inherent clinical inconsistencies 
include variable definitions, large variation in incidences 
depending on the sensitivity of preoperative imaging (for 
example mammography versus MRI), underestimating the 
tumour load using the current TNM staging classification 
and unknown clinical implications of MIBC, where MF 
cancers may be clinically and genetically distinguishable 
from MC ones (5,14,29). 
Clinical cancer outcomes after breast-
conserving surgery versus mastectomy for MIBC 
Six (20,32-35,42) of seven studies reported clinical 
outcomes for BCS versus mastectomy for MIBC, which was 
the primary aim of the review, with a median follow-up of 
59.5 (IQR, 56–81) months. The largest of the seven studies 
was part of the multicentre BRENDA cohort study (17), but 
did not provide raw data for comparison. This was scored 
as having moderate quality based on analyses of clinical 
subgroups, judged to be adherent to German guidelines 
or not. Adherence to guidelines meant that BCS was 
contraindicated for MC cancers (17). Non-conformance 
with guidelines resulted in 12.9% of MC cancers (60 
of 464) being treated with BCS, compared with 46.8% 
(217 of 464) undergoing mastectomy (17). LRR was 
reported in five studies (15,42-45), distant metastases in 
three (15,42,43), overall survival in four (42-45) and DFS in 
two (17,44). 
Local recurrence
Six studies (15,25,42-45) reported LRR rates ranging from 
2% to 23% after BCS, with apparently similar rates of 
LRR for BCS compared with mastectomy. There was no 
heterogeneity in these studies, in part reflecting similar case 
selection biases with surgeons choosing BCS for low-risk 
patients and mastectomy for high-risk cases. Overall, the 
results are inconclusive and compromised by study quality.
The historical study of Yerushalmi and colleagues (25) 
reported the potential clinical equivalence of mastectomy 
in 887 patients compared with standard BCS in 300 
patients, with 10-year LRR rates of 5.5% vs. 6.5% among 
887 women undergoing mastectomy respectively (P=0.95). 
A significant limitation of this article was the lack of 
raw data comparing types of surgery in treating MIBC. 
Five-year LRR rates of MIBC in this study were 4.5% after 
mastectomy vs. 2.5% after BCS (25). This further attests to 
the limitations of clinician bias in the comparability of BCS 
to mastectomy in such studies. 
Survival
Wolters and colleagues (17) concluded that treatment of 
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MF cancers according to German guidelines by BCS (683 
of 1,398, 48.9%) vs. mastectomy (329 of 1,398, 23.5%), 
showed no significant differences in 5-year recurrence-
free survival. Neri and co-workers (15) showed that MF 
cancers were a significant independent predictor of worse 
breast cancer-specific survival for BCS (HR =3.88, 95% 
CI: 1.06–14.12, P=0.026) and mastectomy (HR =2.72, 
95% CI: 1.15–6.48; P=0.023). Kadioğlu et al. (45) reported 
significantly better 5-year survival of 92% (median 
95 months; range, 91–99 months) after BCS in 119 patients, 
compared with 72% (median 73 months; range, 68–78 months) 
after mastectomy in 103 patients (P<0.001). Multivariable 
analyses in the latter study, accounting for intergroup differences, 
subsequently showed no significant effects on outcomes 
between types of surgery (P=0.07) (45). Similarly, Kaplan and 
co-workers (42), Nos and colleagues (43) and Lim et al. (44) 
reported no differences in overall survival, DFS or distant 
metastases by type of surgery. 
Current recommendations and practice 
Two surveys  of  UK surgeons  were  conducted in 
collaboration with the Association of Breast Surgery in 
2013 and 2015, respectively (personal communication ZE 
Winters). Ninety per cent of surgeons strongly expressed 
their support for a clinical trial addressing the clinical 
safety of BCS compared to mastectomy ± reconstruction 
in the treatment of MIBC. There appeared to be greater 
uncertainty regarding the optimal treatment of MF cancers, 
compared to assured recommendations for mastectomy 
in the case of MC cancers expressed by 80% of surgeons. 
Sixty to 70 per cent of surgeons reported their uncertainty 
about recommending BCS for MF cancers and were 
genuinely unconvinced by current evidence suggesting the 
comparable clinical safety of BCS to mastectomy. Based 
on the systematic review, surgeon’s surveys and Patient 
public opinion, a National Institute of Health Research 
funded (Research for Patient Benefit: PB-PG-1215-20009) 
randomised controlled trial called MIAMI will commence 
patient recruitment across multiple UK centres in 2018 
(1,8). This is a feasibility study to evaluate the presence of 
collective clinical equipoise amongst patients and health 
care providers. The importance of the scientific questions is 
further underlined by an on-going USA prospective cohort 
study called the ACOSOG [American College of Surgeons 
Oncology Group) Z11102] (8,41). This cohort study is 
however limited in its comparability to outcomes relating 
to the current standard of care by excluding a control 
mastectomy arm. 
Overall, there was limited evidence of moderate 
quality evaluating the clinical equivalence of BCS versus 
mastectomy for treating MIBC (1,8). Factors limiting the 
quality of evidence were study designs, heterogeneous 
clinical outcomes, and few if any representative studies 
of use of BCS to treat MC tumours compared with MF 
cancers. Most studies did not address the primary aim 
of the systematic review, but compared BCS for MIBC 
versus unifocal cancers (1). The apparent lack of significant 
intergroup differences in the rates of LRR support the 
rationale for a randomized trial. It is also poorly conceived 
to suggest that there is evidence of comparable rates of 
LRR reported by studies comparing BCS for MIBC to 
unifocal cancers (1). Despite this, Houvenaeghel et al. (4) 
and Nijenhuis et al. (3) in two recent reviews exclusively 
consider studies evaluating clinical outcomes following BCS 
for MIBC compared to unifocal cancers. 
Currently the pathogenetic mechanisms underlying 
MIBC versus unifocal cancers are unknown (10,29). Despite 
uncertainties based on the evidence, Houvenaeghel et al. 
have recently suggested that the rate of local recurrences 
is usually low after BCS of MIBC, and proceed to propose 
that BCS is a reasonable option for MIBC (MF/MC) in 
women aged 50–69 years with small cancers and absence 
of extensive DCIS (4). In this article, the term breast 
conserving treatment (BCT) suggests the implicit adoption 
of the adjuvant medical treatments and radiotherapy 
producing synergistic benefits in clinical outcomes (4). 
In the systematic review (1), only two studies (16,26) 
described neoadjuvant chemotherapy. Modern neoadjuvant 
chemotherapy results in high rates of pathological complete 
responses in 60–70% of patients, especially in HER2 over-
expressing and triple-negative cancers (46). Ataseven and 
colleagues (16) reported that neoadjuvant chemotherapy-
induced pathological complete cancer response rates in 
MIBC increased the surgical options for BCS without 
compromising clinical outcomes, an approach requiring 
future investigation. In the absence of a pCR, MC cancers, 
but not MF cancers had a worse 3-year DFS (75.6% vs. 
81.3%) and 3-year OS (84.7% vs. 88.2%) compared to 
unifocal cancers (P=0.009). 
BCS with radiotherapy is widely accepted as an 
alternative to mastectomy in the treatment of early 
stage breast cancer (3,40). The 20-year follow-up of the 
National Surgical Adjuvant Breast and Bowel Project B-06 
trial showed a local recurrence of 14.3% after BCS and 
radiotherapy (RT) (47). The effectiveness of boost RT 
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to decrease LR has been established in a selected high-
risk group of women aged 50 years or younger (48). In 
the systematic review, there was no mention of more than 
one lumpectomy bed receiving a tumour bed RT boost in 
MC cancers; however, there were only 223 MC cancers 
treated by BCS out of 3,537 women with MIBC (1). 
Consequently, there is currently no substantive evidence for 
the comparable safety and cosmetic acceptability of using a 
double RT boost after double lumpectomies in MC cancers 
compared to the EORTC boost trial (48). This question 
will be a novel area of investigation within the MIAMI trial 
(1,8). The feasibility of using double radiotherapy boosts 
will be evaluated for its safety and cosmetic results within 
the MIAMI trial (1,8). Bartelink et al. showed that boost 
RT in addition to 50 Gy of whole breast irradiation in 
unifocal cancers increases the 10-year rate of severe fibrosis 
from 1.6% to 4.4%, and of moderate fibrosis from 13% to 
26% (48). Houvenaegehl et al. (4) conducted a dosimetric 
study to evaluate the volume of breast receiving an 
increased dose of RT in patients treated in the classical 
manner and in patients treated with a double boost. A 
second RT boost resulted in a 14% increase of the volume 
of breast receiving more than 55 Gy (from 19% to 33%), 
and a 10% increase of the volume of breast receiving more 
than 60 Gy (from 15% to 25%) (4). Overall, the ipsilateral 
whole breast received a mean 2 Gy increased dose of RT, 
whose clinical significance is unknown (4). Bracketing wires 
and 1,125 seeds should be used to localize and delineate the 
disease extent, applicable to either MF or MC cancers (49). 
There is a potential role for neoadjuvant chemotherapy or 
endocrine therapy if the involved breast cancer volume is 
too large, however there is a poor evidence base for BCS 
in this context, with no a priori randomised trials, other 
than the subset analysis within the GEPAR trials (16,46). 
The poorer prognostic implications of MIBC compared 
to unifocal cancers underlines the importance of adjuvant 
systemic treatments in all women, independent of the type 
of surgery. The MIAMI trial (1,8) proposes the prospective 
collection of patient reported quality of life questionnaires 
using the EORTC QLQ-C30, QLQ-BR23 and the EQ5D-
5L (50) and standardised evaluations of cosmetic outcomes 
using the Breast Cancer Conservative Treatment cosmetic 
(BCCT.core) (51), which is a digital software program 
for evaluation of cosmetic outcomes previously validated 
in the TARGIT-A trial (52). Two validated quality of life 
questionnaires have been developed for women undergoing 
breast reconstruction called the BREAST-Q (50) and the 
EORTC BRECON23 (53), however neither have been 
robustly validated for therapeutic mammoplasty (TM) 
procedures using EORTC guidelines. 
TM 
The topographical localisation of MF or MC cancers 
must be considered in different regions of the breast and 
to the distance of the nipple-areolar complex (54). The 
new MIAMI trial has proposed a pragmatic distinction of 
either MF or MC cancers (Figure 1). MF cancers within 
the MIAMI trial will be defined as resettable by a single 
larger lumpectomy, compared to MC cancers definitively 
requiring at least two distinct lumpectomies (1). TM 
techniques comprise either extended breast tissue excisions 
for cancer(s) with simple re-approximation of breast tissue 
(level 1 re-coning) or a therapeutic reduction mammoplasty 
(level 2) (55,56). A comprehensive classification describing 
a breast quadrant per quadrant atlas for many oncoplastic 
surgical procedures has been proposed by Clough et al. (2010 
and 2012, respectively) (57,58) reporting low re-operation 
rates, low risks of delayed adjuvant treatments and good 
cosmetic results. Clough et al. (59) also describe comparable 
rates of microscopically positive cancer margins following 
oncoplastic BCS (10/58, 17.2%) for MF versus unifocal 
cancers (23/217, 10.6%). Currently, TM is the standard 
best practice for optimizing cosmetic outcomes after 
extended breast tissue excisions relative to breast volume. 
Recently, a small case series (60) (68 patients) describing 
BCS for 20 patients with MF cancers was reported. In 
principle, treating MC cancers using two or more separate 
wide local excisions combined with TM merits future 
investigation, particularly in the context of RT boost(s) to 
one or more tumour beds. A meta-analysis (55) comparing 
3,165 TM procedures with standard BCS in 5,494 patients 
with unifocal cancers showed that the former significantly 
reduced rates of cancer margin positivity (P<0.001) and 
surgical re-excisions (P<0.001) (61,62). Recently, the St 
Gallen panel (40) recommended a minimal acceptable 
surgical margin of “no ink on invasive tumour or DCIS”. 
Other interventions significantly reducing intraoperative 
tumour margin positivity have been described: digital 
specimen radiology (P=0.012 for digital vs. conventional 
mammography) (63), tumour margin cavity shaves (64) and 
real-time cancer margin assessments (19,65).
MF and MC breast cancer is regularly considered a 
relative contraindication for BCT (40). There are two 
reasons for this wide spread notion: (I) perceived higher 
risk for in-breast recurrence since it is assumed that in MF/
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MC cancer the risk of more invasive foci in the breast is 
greater, and therefore radiotherapy possibly less effective; 
(II) less good cosmetic outcome due to wider excisions, 
either segmental resection or quadrantectomy in multifocal, 
or multiple wide local excisions in MC disease. Mastectomy 
is therefore the treatment of choice for MF/MC breast 
cancer. Initial attempts at BCS for MF/MC breast cancer 
was met with little enthusiasm because early studies 
reported poorer local control for multiple ipsilateral breast 
lesions when compared with similar treatment for unifocal 
lesions (1). However, there is a growing body of evidence 
which suggests acceptable local control rates with MF/MC 
breast cancers treated with BCS, provided negative margins 
for each malignant focus and reasonable cosmetic outcomes 
(1,8). One of the possible barriers limiting BCT for MF/
MC is the ability to fulfil guideline recommendations for 
the resection of all tumor foci through a single incision 
(57-59). MC lesions have either been treated with 
mastectomy or approached through two incisions 
(57-59). The latter approach may contravene current 
guidelines (66). Various oncoplastic techniques have been 
described to expand indications for BCS without significant 
compromise of cosmesis. Three factors are taken into 
consideration for surgical planning: skin and subcutaneous 
tissue, resection pattern and parenchymal repair (57-59). 
Thus, modifications of previously considered standard 
Figure 1 Definition of MIBC in the MIAMI trial. A “disease site” is defined as at least one invasive cancer plus one or more either invasive 
or non-invasive (microscopic intraductal/DCIS) cancers separated by radiologically normal tissue. Multifocal (MF) is one “disease site” 
requiring one lumpectomy; multicentric (MC) is two or more separate and distant “disease site” requiring separate lumpectomies. The 
secondary “disease site” may comprise only DCIS in MC cancers. Local site multidisciplinary consensus will confirm whether MF or MC 
cancers requiring either one or separate “disease site” excisions separated by normal tissue Radiologically normal refers to standard imaging 
(mammogram, ultrasound and MRI). The largest clinical (standard imaging) cancer focus permissible is: 30 mm as part of MF or MC “disease 
site”; 30 mm may include the size of a single cancer and its surrounding small satellite cancers. Cancer A, invasive; cancer B, invasive; cancer C, 
DCIS; MIBC, multiple ipsilateral breast cancer; DCIS, ductal cancer in situ.
30 mm largest 










30 mm largest 
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approaches might be necessary to allow a transition in 
treatment concept.
Current and future translational studies evaluating 
potential field defects 
Identifying epigenetic changes in adjacent normal breast 
cancer tissues is likely to be important for understanding 
the aetiology of breast cancer, especially in the context 
of clinically diagnosed MIBCs (10). It remains unknown 
how epigenetic field defects comprising DNA methylation 
alterations contribute to carcinogenesis (10). Epigenetics is 
defined as heritable changes in gene regulation independent 
of DNA sequences. Direct effects on the DNA comprise the 
addition of a methyl group at cytosines of CG dinucleotides 
(commonly referred to as “CpGs”) (67). Teschendorff et al. 
analysed the DNA methylome of 569 breast tissue samples, 
including cancer free women (n=50) and matched normal 
cancer pairs (n=84) (10). Tens to thousands of epigenetic 
alterations comprised differentially variable methylated 
CpGs (DVMC cancers) that were more variable and 
hypermethylated in normal tissue (epithelial or stromal 
cell compartments) adjacent to breast cancers, including 
the cancers themselves (10). Normal tissues adjacent to 
breast cancers exhibited a significantly higher load of 
epigenetic changes field defects in stage-2 compared to 
stage-1cancers with adverse clinical outcomes (10). DVMC 
cancers identified cells that progressed to breast cancer with 
increased DVMC cancers in DCIS (10). The significant 
hotspots of epigenetic modulation mapped to the WNT 
(stem cell differentiation pathway) and FGF signalling 
pathways comprising promoter hypermethylation in the 
normal adjacent tissue surrounding breast cancers, unlike 
that in normal tissue from cancer-free women (10). 
Future randomised clinical trials 
A world-first randomised controlled trial called MIAMI 
(Safe Surgery for Multiple Breast Cancers) has been 
ethically approved in multiple UK centres (1,8). This 
will commence as a 3-year feasibility study and aims to 
recruit a total of 50 women with MIBC to evaluate the 
acceptability of women accepting the rationale for a trial 
based on current evidence, including their willingness to 
be randomised (1). The 1:1 randomisation will comprise 
allocation to either multiple lumpectomies and all types of 
TM (levels 1 and 2 including chest wall perforator flaps) 
or to the standard treatment of mastectomy and/or breast 
reconstruction (1,8). MIAMI is ethically approved and is 
a National Cancer Research Network (NCRN) portfolio 
study (1,8). The trial has proposed pragmatic definitions for 
MF or MC cancers and recommends diagnostic breast MRI 
alongside standard imaging (1,8) (Figure 1). A successful 
feasibility study will proceed to the main trial predicated 
on lessons learnt during the feasibility study. Importantly, 
the main MIAMI trial will evaluate the genomics of each 
breast cancer focus and their surrounding stromal tissues. 
In future, this diagnostic information may be fundamental 
in determining appropriate surgery recommendations 
based on cancer and/or stromal genomics. The MIAMI 
trial will evaluate individual patients requiring up to two 
lumpectomy radiotherapy boosts potentially recommended 
in some MC cancers (4). Dual boost RT is a novel 
therapeutic intervention using IMPORT HIGH and FAST 
FORWARD trial procedures with trial results pending, 
and demanding future assessments of cosmetic and patient 
reported outcomes (4,40,53).
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